Profund Advisors LLC Buys 24,360 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Profund Advisors LLC increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 75.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,624 shares of the biopharmaceutical company’s stock after buying an additional 24,360 shares during the period. Profund Advisors LLC owned 0.06% of Ultragenyx Pharmaceutical worth $1,302,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Covestor Ltd grew its stake in Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 369 shares in the last quarter. Huntington National Bank raised its stake in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares in the last quarter. Xponance Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 3.1% during the third quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 406 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 6.9% in the third quarter. Amalgamated Bank now owns 7,226 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 469 shares during the period. Finally, Arizona State Retirement System boosted its holdings in shares of Ultragenyx Pharmaceutical by 2.2% in the third quarter. Arizona State Retirement System now owns 25,176 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 533 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $23.37 on Thursday. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -3.82 and a beta of 0.39. The firm has a 50-day simple moving average of $23.18 and a two-hundred day simple moving average of $26.22. Ultragenyx Pharmaceutical Inc. has a one year low of $18.29 and a one year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The firm had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm’s quarterly revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.57) EPS. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the sale, the executive vice president owned 76,346 shares in the company, valued at approximately $1,740,688.80. This represents a 9.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Theodore Alan Huizenga sold 1,632 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $37,209.60. Following the completion of the sale, the chief accounting officer directly owned 48,670 shares of the company’s stock, valued at $1,109,676. The trade was a 3.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 117,262 shares of company stock valued at $2,687,403 over the last quarter. Insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Canaccord Genuity Group reduced their price objective on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Morgan Stanley upped their target price on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, April 16th. Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. HC Wainwright cut their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Finally, Wall Street Zen downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $60.41.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.